Search

This week is the expiration of March options, and the good news is we appear to be headed to full profits on four of our March positions (JCI, SONO, GS, APHA) and are in good shape with our one position that is unlikely to be called away Friday (DT). Expect to hear from me Thursday afternoon or early Friday morning on these expiring covered calls.

U.S. stocks struggle a bit to regain momentum as Hong Kong’s Hang Seng and China’s Shanghai Composite contract. Investors seem to be taking a close look at valuations as markets from Japan to Europe trade at lower valuations. The big $3.5 trillion spending bill is spooking U.S. markets and splitting U.S. Senators. Today our new recommendation is a play on the aging baby boomer generation, which will increasingly require more medical attention.

Today we are jumping into a small-cap biotech company that has a drug delivery platform that could completely revolutionize how injectable drugs are delivered.

The short version is that millions of people that require injections could, if all goes well, just take a pill instead.



While the risks are meaningful with any biotech, so too is the potential. Early data shows this platform works, and already there are programs being designed to deliver treatments for osteoporosis, Type-2 diabetes and arthritis.



It’s all inside this month’s Issue.

The best dividend stocks to buy and hold have long dividend histories, generate reliable cash flow and are recession-resistant. Here are the 10 I like best.

The best small-cap stocks don’t necessarily reside - or stay - in their signature index, the Russell 2000. Here’s a better way to find them.

Small caps have hit a valuation metric they haven’t touched since 2012. And that bodes well for a nice bounceback in 2019.

By interpreting certain signals from its chart, I rode Square stock to some big gains in 2017-2018. To find the next Square stock, here’s what to look for.

I issued a recent call option buy recommendation on SHOP stock after the stock was slammed by Citron. The result was a 171% profit in one month!

Last week brought a wave of earnings gaps among growth stocks, with some leaping more than 20%. But not all gaps are created equal. Here’s what I mean.

Mike Cintolo shares all his thoughts on the stock market’s historic crash, including some scenarios that are possible going forward.

Berkshire Hathaway had to alter its annual meeting this year, but Warren Buffett’s company remains strong. Here are 4 Berkshire Hathaway stocks to consider.

Last week I traveled to Las Vegas for a cannabis conference. I got much more than I bargained for: cowboys, a rodeo, and Mike Tyson! Here is my story.

Growth stocks are riding high right now, but value stocks look better positioned for future growth in this market. Here are 10 undervalued gems that I love.

Small-cap biotech IPOs are popping up everywhere, but it’s important to separate the good from the bad. These four are worth putting on your watch list.

The huge run-up in Facebook stock these last few years has paralleled the major growth in the company’s mobile ad sales. It’s not a mere coincidence.

Want to find the best growth stocks? Look no further than the stocks that are already advancing, with the potential to go much higher.

After peaking in January, marijuana stocks have had a rough go these last six months. And that could make this the perfect time to buy them again.

Keurig Green Mountain just bought Dr Pepper Snapple, prompting a 25% overnight gap up in Dr Pepper stock. It’s why you should always own takeover targets.